384 B-type natriuretic peptide plasma levels is a good marker in estimating cardiac hemosiderosis in patients with β-thalassemia major

2005 ◽  
Vol 4 (1) ◽  
pp. 84-85
Keyword(s):  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Thalassemia Major ◽  
Good Marker

scholarly journals Diagnostic Value of Plasma Levels of Brain Natriuretic Peptide in Arrhythmogenic Right Ventricular Dysplasia

Circulation ◽  
1998 ◽  
Vol 98 (22) ◽  
pp. 2433-2440 ◽  
Author(s):  
Kiyotaka Matsuo ◽  
Toshio Nishikimi ◽  
Chikao Yutani ◽  
Takashi Kurita ◽  
Wataru Shimizu ◽  
...  
Keyword(s):  
Brain Natriuretic Peptide ◽  
Right Ventricular ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Arrhythmogenic Right Ventricular Dysplasia ◽  
Diagnostic Value ◽  
Right Ventricular Dysplasia

Effect of Head-Out Water Immersion on Atrial Natriuretic Peptide Plasma Levels in Cirrhotics with Ascites

1986 ◽  
Vol 8 (6) ◽  
pp. 1303
Author(s):  
A. Fernandez-Cruz ◽  
D. Rodriguez-Puyol ◽  
J. Gutkowska ◽  
J. M. Lopez-Novoa
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Water Immersion ◽  
Atrial Natriuretic

Determinants of B-type natriuretic peptide plasma levels in the chronic phase after heart transplantation

2004 ◽  
Vol 23 (2) ◽  
pp. S98
Author(s):  
R Klingenberg ◽  
A Koch ◽  
Ph.A Schnabel ◽  
C Gleissner ◽  
A Remppis ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Chronic Phase

scholarly journals N-terminal Pro-brain Natriuretic Peptide plasma levels are Associated With a Short-Term Diagnosis of Cancer in Patients with Coronary Artery Disease

2020 ◽  
Author(s):  
José Tuñón ◽  
Álvaro Aceña ◽  
Ana Pello ◽  
Sergio Ramos-Cillán ◽  
Juan Martínez-Milla ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
High Sensitivity ◽  
Short Term ◽  
Artery Disease

Abstract Background N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels are increased in patients with cancer. In this paper we test whether NT-proBNP may identify patients who are going to receive a future cancer diagnosis (CD) in the short term. Methods We studied 962 patients with stable coronary artery disease and free of cancer and heart failure at baseline. NT-proBNP, galectin-3, monocyte chemoattractant protein-1, high-sensitivity C-reactive protein, high-sensitivity cardiac troponin I (hsTnI), and calcidiol (vitamin D) plasma levels were assessed. The primary outcome was new CD. Results After 5.40 (2.81-6.94) years of follow-up, 59 patients received a CD. NT-proBNP [HR 1.036 CI (1.015-1.056) per increase in 100 pg/ml; p=0.001], previous atrial fibrillation [HR 3.140 CI (1.196-8.243); p=0.020], and absence of previous heart failure [HR 0.067 CI (0.006-0.802); p=0.033] were independent predictors of a receiving a CD in first three years of follow-up. None of the variables analyzed predicted a CD beyond this time. A previous history of heart failure was present in 3.3% of patients receiving a CD in the first three years of follow-up, in 0.0% of those receiving this diagnosis beyond three years, and in 12.3% of patients not developing cancer (p=0.036). Conclusions In patients with coronary artery disease, NT-proBNP is an independent predictor of CD in the first three years of follow-up but not later, suggesting that it could be detecting subclinical undiagnosed cancers. The existence of previous heart failure does not account for these differences. New studies in large populations are needed to confirm these findings.

Sign in / Sign up

Export Citation Format

Share Document